31 October 2025

Oncoinvent appoints Dr. Ramzi Amri as new CFO

Oncoinvent ASA (OSE: ONCIN) today announces the appointment of Dr. Ramzi Amri, M.D., Ph.D. as Chief Financial Officer (CFO), effective on or around 15 January. 

251031 Oncoinvent CFO PR

Dr. Amri succeeds Tore Kvam, who has served as CFO since 2019. The company would like to thank Mr Kvam for his valuable work and dedication over the past years. “During his seven years in  Oncoinvent, Tore Kvam has worked tirelessly to contribute to Oncoinvent’s development and  performance. We’re very grateful for his contribution,” says Øystein Soug, CEO of Oncoinvent. 

 

Dr. Amri joins Oncoinvent from Galapagos NV, where he most recently served as Vice President and Head of Development Strategy & Execution. He brings broad international experience through  leadership positions in strategy, operations, and corporate transformation across the life sciences  and healthcare industries. Dr. Amri also brings seven years of management consulting experience  from McKinsey & Company, advising global pharma and biotech clients, as well as financial  institutions and private-equity-backed businesses, on growth, M&A, and organizational transformation. 

 

Dr. Amri holds an M.D. and a Ph.D. from the University of Amsterdam. He conducted his Ph.D.  research and completed a postdoctoral fellowship in surgical oncology and epidemiology at Harvard Medical School and Massachusetts General Hospital, where he initiated and led a research program in colorectal cancer.  

 

“We are pleased to welcome Dr. Amri to Oncoinvent’s management team,” says Øystein Soug, CEO of Oncoinvent. “His strategic and financial leadership, together with deep industry knowledge, will be instrumental as we advance our clinical programs and continue building long-term value for patients  and shareholders alike.” 

 

About Oncoinvent 

Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical  therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting  radionuclide radium-224, directly targeting micro-metastases in the peritoneum post-surgery,  harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical  development program in two indications. One Phase 1 trial and one Phase 1/2a trial have been  completed and one randomized Phase 2 trial in ovarian cancer is currently ongoing in the US and  Europe. Early clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. Oncoinvent runs a state-of-the-art manufacturing facility to produce  drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Oslo Stock Exchange. 

 

About Radspherin®  

Radspherin® is an innovative internal radiation therapy designed to directly target microscopic  metastases in the abdominal cavity following surgery. Radspherin® is currently in development as a  post-surgical treatment for patients with cancer that has spread to the abdominal cavity — a group  with very limited treatment options today. The drug candidate offers a distinctly unique therapeutic approach with several differentiating features, including the use of radium-224, single-dose  treatment with a sustained therapeutic effect, non-systemic administration, direct targeting and an  exceptional dose-to-tumor ratio, maximizing efficacy while limiting harm to healthy tissue 

 

Forward-Looking Statements 

All statements other than statements of historical facts contained in this press release are forward– looking statements and are not a representation that Oncoinvent’s plans, estimates, or expectations  will be achieved. These forward-looking statements represent Oncoinvent’s expectations as of the  date of this press release, and Oncoinvent disclaims any obligation to update the forward-looking  statements. These forward-looking statements are subject to known and unknown risks and  uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results  of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the  benefits of our tests and product offerings to patients, providers and payers. 

 

For further information, please contact:

Oystein Soug, Chief Executive Officer 
Email: soug@oncoinvent.com

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.  

Mr. Soug holds an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close